What AB 1990 would do AB 1990, authored by Assemblymember Mike Gipson, targets compounded GLP1 drugs used for obesity or weight management
Weight loss averages 3-5% of body weight
The Food and Drug Administration has repeatedly cautioned consumers against unapproved, compounded, or counterfeit weight-loss products circulating outside authorized supply chains
Ozempic, and similar drugs developed for treatment of Type 2 diabetes, have a lot in common with the old saying the good, the bad, and the ugly. Good is the serendipitous finding that the drugs promote significant weight loss
Dos: Eat smaller meals Drink plenty of water Keep your head elevated while sleeping Donts: Use straws (can introduce excess air into the stomach) Lie down immediately after eating Eat overly spicy, greasy, or sugary foods Constipation Clinical trials have found that 23.4% of participants experienced constipation while on semaglutide